February 2015 Work Group Recaps:


Work Group 1 Telecommunication

DERFs/ECLs Reviewed:
- DERF 001213 was pended in August and November for more work by WG1 Telecommunication FAQ Task Group. The DERF was approved.
- DERF 001214/ECL 000164 was pended in August and November for more work by WG1 Telecommunication FAQ Task Group. The DERF/ECL was approved as modified.
- DERF 001240 was pended.
- DERF 001241/ECL 000170 was denied.
- DERF 001242/Emergency ECL 000171 was approved as modified.
- DERF 001243/Emergency ECL 000172 was approved.
- DERF 001244/Emergency ECL 000173 was approved.
- DERF 001245 was withdrawn.
- DERF 001246/ECL 000174 was approved.

Old Business:
- A HIPAA Standards, Operating Rules, and regulations (HPID/ICD/NPI/EFT/ERA) update was given.
- Use of Quantity Prescribed (46Ø-ET) in the Telecommunication Standard claim billing - Note this field would be required for Part D Schedule II Controlled Substance claims; however the use of this field is not limited to Part D claims only.
  - Telecom D.0 and all versions from that point have been updated (November 2012).
  - 03/2014 NCPDP received a response from HHS to the 03/2013 letter. The change will go through NPRM and Final Rule process.
    - We have asked that the industry have input on the implementation timeframe before the NPRM is published.
    - We have asked for timeframe of NPRM publication.
  - 06/2014 Update: OESS has responded that an NPRM including Quantity Prescribed and SCRIPT electronic prior authorization is going through the review process.
  - WG1 Telecommunication FAQ Task Group brought forward a recommendation timeframe for Quantity Prescribed regulation implementation for OESS.
- NCPDP SNIP Committee met once to provide input on the NCVHS Review Committee questions on the criteria for standards. 2 additional meetings are scheduled for February to finalize the input and address questions on operating rules.
  - During the November 2014 meetings there was initial discussion for the naming of the next version of Telecom, Batch, and Subrogation Standards in HIPAA, as well as evaluation of other standards to be named in HIPAA. NCPDP Staff provided draft timelines and evaluation documents for the industry to use as starting points to plan future work. WG1 and WG9 discussed these documents and established the version balloted out of the August 2016 meeting would be the next Telecommunication Standard to be adopted under HIPAA. SNIP was tasked with further analysis and coordination.

Task Groups:
- The **Telecommunication FAQ Task Group** discussed questions submitted. They worked on pended DERFs 001213 AND 001214/ECL 000164.
• The **Coordination of Benefits Task Group** discussed questions submitted. Question 54 was reviewed and participation is needed on the COB calls to assist in drafting a response. Question 56 was reviewed, approved and it will be published in the Editorial Document.

• The **Financial Information Reporting Task Group** brought forward FAQs which were approved for the FIR Editorial document.

• **Information Reporting Problems Task Group** is preparing a SPAP ADAP TrOOP Attestation document and process. They are preparing chapters on SPAP ADAP data exchange. They are also preparing guidance on Information Reporting (Nx) transaction matching logic and guidance for TrOOP eligible supplemental payers.

• The **Post Adjudication Task Group** is on hiatus.

• The **Definition of a Valid Prescriber Task Group** brought forward DERF 001242/Emergency ECL 000171, DERF 001243/Emergency ECL 000172, and DERF 001244/Emergency ECL 000173. The task group has been working on questions regarding the new CMS enrollment rule for prescribers. This also affects pharmacists who prescribe. They are waiting for guidance from CMS. They also reached out to the DOJ for an understanding of the prescriber enrollment workflow for DEA. FAQs were also reviewed and approved.

• **Supplemental Payer Reporting Task Group** changed the task group name to **Part D Supplemental Payment Reporting**. The task group continued to review the Part D Plan Nx Performance Reports Guide.

• **Eligibility Verification Enhancements Task Group** did not meet.

• **Compound Billing Solutions Task Group** did not meet and was disbanded.

• The **Transaction ID Task Group** is examining the use of a unique transaction identifier for all Telecom transactions. They brought forward DERF 001245.

• **Vaccine Services Task Group** has discussed medical enrollment and billing of vaccines by pharmacies.

• **Benefit Integration Task Group** did not meet as they are monitoring the ballot.

• **Standardized Subrogation Task Group** has begun to review what would be needed in a standardized format for all subrogation. The task group needs examples of any processes or formats that are currently being used for any non-Medicaid subrogation.

**Work Group 2 Product Identification**

**Task Groups:**

• The **Structure Product Labeling Activities Task Group** tracks the activities of the SPL, offers suggestions to improve access and usability of the FDA Structured Product Label and Electronic Drug Listings, and monitors the work of the Guiding Coalition for feedback to the work group. The Coalition has sent 19 letters to the FDA and is working on three additional letters of recommendation.

• The **Product Review and Billing Unit Exception Task Group** is reviewing the exceptions within the Implementation Guide and issues that result from changes to existing products or release of new products.
  
  • Discussed and compiled a list of lessons learned regarding billing unit changes.
  
  • Comments to the BUS DERF reviewed at the November 2014 WG2 meeting were reviewed with the submitter. Two comments remain and will be adjudicated during the next quarter meetings of the task group.
  
  • Reviewed seven new QUIC forms and submitted them to WG2 for final adjudication.
- The **NCPDP Product Identification Standard Task Group** will follow the ballot submitted for changes to the NCPDP Product Identifiers Standard Implementation Guide. The task group met and adjudicated the remaining two comments that were submitted for the previous ballot requesting approval of the standard. A copy of the Product Identifiers Standard was forwarded to the FDA since it has been referenced many times in our discussion with the FDA.

- The **SPL REMS Requirements Task Group** is to gather the data needed to develop a template for pharmaceutical manufacturers to use in electronic submission of all the components for risk evaluation and mitigation strategies (REMS) drugs to a central repository (DailyMed) via FDA's Structured Product Labeling system. FDA published a Federal Register Notice 9-23-2014 announcing the 4 priority projects proposed for REMS authorized under PDUFA V as well as a detailed draft report providing rationale for its decision. NCPDP's proposal that REMS be codified and standardized as one of those priorities was adopted by FDA as Priority Project 3: Pharmacy Systems under REMS, Standardizing REMS Information for Inclusion into Pharmacy Systems Using Structured Product Labeling (SPL) under REMS. FDA, an external SPL consultant, and NCPDP have begun drafting an SPL-structured prototype on a fictitious drug for stakeholder feedback. A webinar ("REMS and SPL Overview") will be presented to the HL7 SPL Technical Team on February 9, 2015 to update these SPL experts on the current progress of FDA efforts to standardize and codify REMS via SPL and solicit their further input. A joint meeting of WG1, WG2, and WG11 was held on February 6 to describe the path forward with SPL and solicit feedback on implementation.

- The **Dates Associated with Pharmaceutical Products Task Group** investigates definition inconsistencies, involves government agencies to make them aware of the issues, and provides education on the importance via a white paper or other means. The white paper has all the pieces needed to be written. Updates to the White Paper will be provided at the next WG2 meeting.

- The **Naming Standards for Drugs, Biologics and Biosimilars Task Group** reported the FDA has not issued any guidance on biosimilar naming. There was an FDA Advisory Committee Meeting for the first biosimilar on January 7, 2015 where John Klimek of NCPDP presented. It is expected this first biosimilar will be approved by March 8th. A presentation on proprietary information on biosimilars was provided and will be posted to the WG2 page of the website once the owner approves the distribution.

- The **Review of Appendix B Reference Code Qualifiers Task Group** is to review the definitions of existing product identifiers for accuracy and update as appropriate. The task group completed their review of the values and definitions within Appendix B. The document with recommendations will be turned over to MC to determine next steps.

- The **Application of the Billing Unit Standard Clarification Task Group** continues to make progress in identifying the rationale used to determine the billing unit from past QUIC forms/products reviews and is capturing the rationale/reasons for those decisions. Once the forms have been reviewed and the results compiled, a guidance document will be written.

- An update on the joint **WG11 and WG2 Drug Description Task Group** was not provided.

- An update on the **MC NDC Depletion Task Group** was provided. See MC meeting minutes.

**New Business:**

QUIC Form Review:
- QUIC #201501 Uceris Rectal Foam
  - BU=grams, total of 66.8 for the carton per Sections 5.4.2 and 4.2.3 of the BUS
- QUIC #201502 Neulasta 6mg/0.6mL NDC 55513-0192-01
  - BU=mL, 0.6 mL per Section 5.2.2 of the BUS
- QUIC #201503 Kitabis Pak NDC 24492-850-56
BU=mL, with a total quantity of 280 per Sections 5.2.1 and 5.5.1 of the BUS

- QUIC #201504 BLINCYTO NDC 55513-160-01
  BU= EACH Kit, quantity of one, per Section 5.5.1 of the BUS
- QUIC #201505 Cosentyx (secukinumab) Injection
  BU=mL per Section 5.2.2 with a quantity of one or two depending on the package dispensed
- QUIC #201506 Selexipag (generic name, brand name has not been announced)
  BU=EACH, with a total of tablets within the package per Sections 5.1.11 of the BUS
- QUIC #201507 NATESTO (testosterone) nasal gel NDC 63481-0239-01
  BU=grams per Sections 5.4.2 and for total quantity dispensed (7.32 grams) with a proposed new FAQ to be scripted that explains the rationale for this decision.

- A request to discuss the previously adjudicated QUIC #201407 Evzio NDC 60842-0030-01 approved as BU=mL per Section 5.2.2 of the BUS by WG2 at the May 2014 meeting. Further discussion did not result in a change to the original decision and WG2 voted to keep the BU=mL per Section 5.2.2 of the BUS.

WG2 will co-lead the WG9 Sub-Task Group on Unbreakable Packages.

Work Group 3 Standard Identifiers

DERF Reviewed:
- DERF 001247/ECL 000175 was pended to the Pharmacy and/or Combination ID Card Task Group to work with the submitter of the DERF on an appropriate solution.

Task Groups:
- The Pharmacy and/or Combination ID Card Task Group reported on the following:
  - WEDI proposal to revise Health ID Card Implementation Guide to reflect the use of the Payer ID in HIPAA transactions rather than the HPID/OEID identifiers. The task group recommended that NCPDP participate in the WEDI Health ID Card Sub-Workgroup to help drive changes as opposed to working independently. The task group will then evaluate the need for revisions to NCPDP’s implementation guide.
  - Use of smart phone technology for benefit identification. The task group will continue researching this technology and will bring forward proposed language for the implementation guide at the May Work Group meeting.
- The Health Plan ID (HPID) Task Group is on hold until CMS responds to NCVHS recommendations regarding the use of HPID in transactions.

New Business:
- WG1 Valid Prescriber Task Group Update (See WG1 Recap)
- WG9 Fraud, Waste And Abuse Training Attestation Task Group Update (See WG9 Recap)

Work Group 7 Manufacturer and Associated Trading Partner Transaction Standards

Task Groups:
- The Reference Guide Task Group did not meet this quarter.
- The Medical/Biologics Task Group did not meet this quarter.
- The Medicaid Drug Rebate Program Task Group identified and ranked core issues for the task group to address. During the next quarter the task group will identify outputs that may come out of resolving each issue and form teams/leaders to work on those issues.
- The Rebate Standard Update Task Group did not meet this quarter.
  - The Specialty Pharmacy Data Exchange Sub-Task Group did not meet this quarter.
The Regulatory Tracking/Pedigree Task Group met to review and discuss the FDA’s draft guidance, “Content and Format of Labeling for Human Prescription Drug and Biological Products.” NCPDP did not submit comments.

The Formulary Management Survey Task Group did not meet this quarter.

New Business:
WG7 received an update from WG9’s OIG Report OEI 05-12-00540 Task Group (see WG9 recap).

Work Group 9 Government Programs

Task Groups:
- The Prescription Monitoring Program (PMP) Task Group presented updated information for states that have prescription monitoring programs. The updated tracking document will be published.
- The 340B Task Group did not meet this quarter.
- The Medicare Part B Claim Billing for Dual Eligibles Task Group did not meet this quarter.
- The Health Insurance Exchange/Marketplace Task Group reported on Special Enrollment Periods and retroactive effective dates (no response to NCPDP’s letter; CMS does not plan to modify the regulations). Stakeholder input (payer, processor, provider and other) is requested regarding challenges currently being experienced or anticipated as a result of the guidance to coordinate payment of premiums and member cost share. During the next quarter the task group will discuss CMS–9944–P, 2016 Draft Issuer Letter and the Proposed Summary of Benefits and Coverage and Uniform Glossary.
- The Medicaid Subrogation FAQ Task Group did not meet as no new questions were received.
- The Medicare Part D FAQ Task Group brought forward two questions and recommended responses for review and approval by Work Group 9. The FAQ document will be updated and published. The task group has three active sub-task groups: NSDE, PDE and Unbreakable Packages. Due to the subject matter of the Unbreakable Packages sub-task group and the needed expertise of WG2, WG9 approved a request to revise the status and name to WG9/WG2 Unbreakable Packages Joint Task Group.
- The Supplemental Payer Part D Reconciliation Standardization Task Group identified two new data elements needed for the standardized reconciliation report. During the next quarter the task group will review the results from the initial testing of the file layout and continue to work on examples.
- The Hospice Task Group developed a scenario grid based on guidance received and the multiple entities that need to communicate/process/respond to the guidance. The task group also completed review of the CMS Hospice FAQs (v.08.06.14) and identified FAQ’s needing clarification from CMS. During the next quarter the task group will address retrospective reconciliation.
- The Standardized Fraud, Waste and Abuse Training Attestation Task Group reviewed the PBM attestation forms submitted by task group members for comparable language and edited for universal appeal. The task group asked the PBMs to have the document reviewed by their legal departments and provide feedback regarding whether to include offshore and anti-kickback language. The task group also contacted NCPDP requesting the organization host the standardized FWA attestation form as part of the existing database. NCPDP has requested additional information from the task group which will be discussed during the next quarter.
- The OIG Report OEI 05-12-00540 Task Group (formerly Manufacturer Patient Cost Share Assistance Programs Task Group) requested the above referenced name change which was approved by WG9. The task group also finalized the Scope and Goals. Initial work began on the first of three identified topics: Types of offers, Stakeholders and Ruling out coverage under Part D.
• WG9 received an update from **WG1’s Standardized Subrogation Task Group** (see WG1 Recap).

New Business:
• WG9 received a Legislative update.

**Work Group 10 Professional Pharmacy Services.**

**DERF Review:**
Pended DERF 001236 was revised “requests revision to the MTM Sections of the Specialized Implementation Guide to reflect requests for MTM and/or pharmacy professional services by entities other than the payer. Added changes: It also seeks to activate <MTMActionCode> for the <MTMRequest>; allow repeat of <TargetedTypeOfService> in <MTMRequest> and <MTMServiceDocumentation>; and update the Code Set sources in the ECL and model for the following elements: <FrequencyOfEncountersApprovedCodeQualifier>, <MTMActionCode>, <ReasonForMTMServiceCode>, <ResultOfActionCode>, <TargetedTypeOfServiceCode> and <Type OfServiceCode>. For consistency all qualifiers for the SNOMED code list will be “LD”. During the meeting a suggestion was made to add the SNOMED Resource page as an appendix to the Specialized Standard to facilitate understanding and adoption. All examples in the implementation guide were updated to use the coded values. The DERF was approved as modified.

Old Business:
• An update was provided on states with laws and regulations in effect or proposed regarding medical marijuana. As discussed in November DERF 001248 to add a marijuana use identifier was submitted and approved with modifications in WG11.
• An update was provided on the United States Pharmacopeia actions to include NCPDP recommendations for allergy reporting, use of mL on packaging and labels for liquid dose forms and use of the universal medication schedule in their next revisions.

**Task Group Reports:**
• **The MTM Communications Task Group** continues to develop new functionality in the Specialty and HL7 CDA standards to support professional pharmacy including submission of DERF 001236.
• **The Acetaminophen Best Practices Hospital Safety Sub-Task Group** has completed the content of the white paper that enumerates best practice guidelines, acetaminophen awareness, tools and technology solutions in a hospital model. Final formatting and editing is underway. WG10 approved the white paper to go forward for publication once the clean-up is complete.
• **WG11 Specialty Requirements for ePrescribing Task Group** is continuing the work to identify Specialty needs and brought forward DERF 001265 to support ePrescribing for Specialty functions in the SCRIPT transactions.
• **WG1-10 Compound Billing Solutions Task Group** has completed all the submitted questions and was disbanded.

New Business:
• Lynnae M Mahaney, Executive Director, Center for Pharmacy Practice Accreditation: Pharmacy provided a presentation on pharmacy practice accreditation

**Work Group 11 ePrescribing & Related Transactions**

**Ballots:**
• Recirculation Ballot WG110062R for the SCRIPT Standard is considered a valid ballot having received the required 69.7% of Consensus Group votes. No new comments were received. See Letter Ballot Comment spreadsheet for the ballot results. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.
DERFs/ECLs Reviewed:

- DERF 001232 was pended in November to the MC PDMP Task Group. The DERF was approved.
- DERF 001248 was approved as modified.
- DERF 001249 was approved.
- DERF 001250 was approved.
- DERF 001251 was approved.
- DERF 001252 was approved as modified.
- DERF 001253 was approved as modified.
- DERF 001254 was approved.
- DERF 001255 was approved.
- DERF 001256 was approved.
- DERF 001257 was approved.
- DERF 001258 was pended for additional work by the Formulary and Benefit Task Group.
- DERF 001259 was pended for additional work by the Formulary and Benefit Task Group.
- DERF 001260 was pended for additional work by the Formulary and Benefit Task Group.
- DERF 001261 was pended for additional work by the Formulary and Benefit Task Group.
- DERF 001262 was pended for additional work by the Formulary and Benefit Task Group.
- DERF 001263 was approved.
- DERF 001264 was pended to the Electronic Prescribing Best Practices Task Group.
- DERF 001265 was approved as modified.
- DERF 001266 was pended to a new Prescription Benefit Inquiry (PBI) and Prescription Benefit Response (PBR) Task Group.
- DERF 001267 was approved.
- DERF 001268 was approved.
- DERF 001269 was approved.
- DERF 001270 was pended for additional work by the Specialty Task Group.
- DERF 001271 was pended for additional work by the Formulary and Benefit Task Group.
- DERF 001272 was approved as modified.
- DERF 001273 was pended for additional work by the Formulary and Benefit Task Group.

Old Business:

- An industry update was provided on NCVHS Subcommittee on Standards, CMS (eprescribing), and DEA eprescribing for controlled substances and implementation activities.

Task Groups:

- The **Formulary and Benefit Task Group** brought forward DERF 001257-001263, and 001271-001273.
- **XML Task Group** reviewed submitted DERFs and brought forward recommendations.
- **NCPDP/HL7 Pharmacist Functional Profile Task Group** the project proposal for release 2 of the Pharmacist profile has been accepted. They will begin development of pharmacy practice specific setting EHR-S R2 functional profiles during the next quarter.
- **WG11 Electronic Prescribing Best Practices Task Group** provided recommendations for the SCRIPT Implementation Recommendations document on rejecting new prescriptions. They also brought forward DERF 001251 and 001255.
- An update was given from the **WG14 LTPAC ePrescribing Task Group**. The group focused its efforts on capturing industry conventions for use of SCRIPT 10.6 in long-term and post-acute care settings, for use by facility vendors and pharmacies that are migrating HL7 interfaces to the SCRIPT Standard (to meet the Medicare ePrescribing standards). They discussed the Census transaction, the
Resupply transaction, and other business requirements. They brought forward DERF 001249, and 001267-001269.

- **REMS and ePrescribing Task Group** has refined their use cases between prescriber, pharmacy, REMS Administrator and switch/intermediary for safe use programs, identifying the data elements needed. They are working through flows from basic REMS to complex REMS exchanges as well as the actual transactions and the updates to the SCRIPT Implementation Guide. They have provided trigger/data element analysis information to the WG2 SPL Task Group. They anticipate a submitting DERF in May for new REMS transactions from prescribers to REMS Administrators.

- The **Electronic Prior Authorization Workflow to Transactions Task Group** determined that the work regarding alternative methods of ePA exchanges (was DERF 001169) be concluded. They discussed pended DERF 001220 (PA Limited Approval). They brought forward DERF 001256. A sub-task group created a short fact sheet document to be given to legislators and implementers which was approved by the members. They brought forward SCRIPT Implementation Recommendations on denying a PACancelRequest.

- The **WG11/2 Joint Drug Description Task Group** discussed injectable product situations from the National Library of Medicine for RxNorm eprescribing names.

- The **Meaningful Use and NIST Test Methods for ePrescribing Task Group** discussed RxCancel request and response test scenarios. NIST is looking to add test scenarios to the eprescribing tool.

- **Implementation of Structured Sig Task Group** is working on examples of more complicated sigs to go in the SCRIPT Implementation Recommendations document.

- **Specialty Requirements for ePrescribing Task Group** requested input from TG participants to identify additional stakeholders. They asked participants to provide examples of information, workflow, etc. to inform discussion. They brought forward DERF 001265 to support ePrescribing for Specialty functions.

### WG14 Long Term and Post Acute Care (LTPAC)

**Old Business:**
- Industry/Regulatory updates were provided which included HIPAA, NCVHS, NY IStop and updated to Medicare Part D guidance on LTC dispensing.

**Task Group Reports:**
- The **ePrescribing Task Group** worked on enhancements to the NCPDP SCRIPT Standard based on the needs of LTC. The Task Group will continue working on guidance for the use of the NCPDP SCRIPT Standard v10.6 for long term and post-acute care setting.

- The **LTPAC Current Billing Issues Task Group** did not meet during the last quarter. They will begin looking at the NCPDP Telecommunication Standard to determine if the long term and post-acute care settings needs are met.

- Received updates from the **WG9 Hospice Task Group**.

### Work Group 16 Property & Casualty/Workers Compensation

**Old Business:**
- An IAIABC update was provided.

**Task Group Reports:**
- The **Legislative/Regulatory Monitoring and Education Task Group** provided an update on state regulatory and legislative initiatives affecting Workers’ Compensation programs.

- The **Billing and State Reporting Task Group** provided an update regarding states moving to adopt regulations for e-billing, standard paper billing and EDI reporting. Updates to the Manual Claim...
Forms Implementation Guide and instructions for billing compounds with more than seven ingredients were discussed.

New Business:
- Discussion on rule comments and advocating for NCPDP standards.

Work Group 45 External Standards Assessment, Harmonization and Implementation Guidance

Old Business:
- Industry updates were provided for WEDI, ASC X12, and CAQH CORE.

Task Groups:
- The Document Revision Task Group did not meet as the review of existing documents found no use of CARC 45 and therefore no modifications were needed.
- The 834/835 FAQ Task Group received no new questions.
- A DSMO Task Group received no DSMO requests for review.

Joint Work Group 1 Telecommunication, Work Group 2 Product Identification, Work Group 11 ePrescribing & Related Transactions

The purpose of the joint session of Work Groups 1, 2, and 11 was to review the current status of NCPDP’s recommended path for using Structured Product Labeling (SPL) as the means for codifying and standardizing Risk Evaluation and Mitigation Strategies (REMS) and the implications for NCPDP implementation. Each of these Work Groups has had a Task Group addressing REMS standardization and implementation; WG 2’s and 11’s remain active. WG 2 was given the lead on NCPDP initiatives until a data standard had been adopted. Considerable momentum has been gained in adopting SPL as the standard for codifying and structuring REMS, in large part because of NCPDP’s leadership.

A presentation was provided that focused on:
- REMS Overview and Standardization Proposal History
- Why SPL as a means to standardize and codify REMS?
- The SPL Data Model
- Status of FDA and HL7 initiatives in support of SPL and REMS
- Possible Uses for SPL Incorporating REMS into ePrescribing

Next steps will be to capture summary information related to the identification of a REMS drug, standardizing the process and flow and building use cases.

MC Maintenance and Control

Ballots:
- Recirculation Ballot WG110062R for the SCRIPT Standard is considered a valid ballot having received the required 69.7% of Consensus Group votes. No new comments were received. See Letter Ballot Comment spreadsheet for the ballot results. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

DERFs/ECLs (see DERF Resolution http://www.ncpdp.org/members/Work-Group.aspx?ID=wgmc)
- 39 new and pended DERFs/ECLs were reviewed (see WG1, WG3, WG10 and WG11 above).
• The DERFs approved at the November 2014 and this meeting will result in five new ballots for the February 2015 ballot period.
  o WG010065 for Telecommunication Standard
  o WG0200005 for Billing Units Standard
  o WG0200006 for Product Identification Standard
  o WG110064 for SCRIPT, Specialized and XML
  o WG110065 for Formulary and Benefit v43

Old Business:
• Updates given:
  o HIPAA
  o NCPDP Legislative/Regulatory Activities

Task Groups:
• The Education/Legislation and Regulations Task Group will be meeting to provide comments on the NPRM for *Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products*
• The NDC Scarcity Task Group received approval for their issues brief and letter to the FDA.
• The PDMP White Paper Task Group
  o Reported on the activities of the S&I Framework PDMP group.
  o Currently they are updating their white paper.

To participate in the PDMP & Health IT Integration Initiative you can “join the initiative” by completing the form on the [PDMP & Health IT Integration Initiative Join wiki page](#).
• The Unique Device Identifier (UDI) Task Group
  o Received a presentation from the FDA on the Unique Device Identifier
  o Will continue working on changes necessary for UDI in the NCPDP Standards
• The Real Time Pharmacy Benefit Inquiry Task Group reviewed results of survey and determined use case for which to begin creating business requirements.
• The Sig in Transactions Task Group completed analysis of NCPDP Standards and determined the Audit Standard was the only applicable one. They submitted a DERF to add a new value for use in the Audit Standard which was denied. There being no further work the Task Group was disbanded.

New Business:
• Attendees received daily Work Group recaps.
• Reviewed New Project Development Form 000039 to create a Public API for SCRIPT, Specialized and Formulary & Benefit. The new project was pended for further clarification from the submitter.